6 citations
,
February 2013 in “Medical Oncology” In this study, researchers reported that the SHBG +5790 G>A polymorphism was associated with an increased risk of developing resistance to hormonal castration in advanced prostate cancer patients.
77 citations
,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
22 citations
,
November 2018 in “Breast Cancer Research and Treatment” In this review, researchers found no evidence of interactions between 5α-reductase inhibitors or spironolactone and endocrine therapies for breast cancer, with no consistent changes in estrogen levels or increased breast cancer risk associated with spironolactone usage.
